{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:52:19Z","timestamp":1779310339239,"version":"3.51.4"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially life-threatening hematologic disease, presenting a myriad of diagnostic and management challenges in children. Here, we provide a review of this disorder and discuss 2 exemplary cases of TTP occurring in adolescents, emphasizing the need for consideration of late-onset congenital TTP (cTTP). We demonstrate the importance of early confirmation of ADAMTS13 enzyme deficiency and the presence or absence of ADAMTS13 inhibitor in order to rapidly initiate the appropriate life-saving therapies. Ultimately, molecular testing is paramount to distinguishing between congenital and acquired immune-mediated TTP.<\/jats:p>","DOI":"10.3389\/fimmu.2022.836960","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T06:14:43Z","timestamp":1649657683000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Molecular Diagnosis Is Vital to the Accurate Classification and Management of Thrombotic Thrombocytopenic Purpura in Children"],"prefix":"10.3389","volume":"13","author":[{"given":"Cecile L.","family":"Karsenty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah L.","family":"Helber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M.","family":"Esquilin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny M.","family":"Despotovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda B.","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.530","article-title":"Clinical and Laboratory Diagnosis of TTP: An Integrated Approach","volume":"2018","author":"Chiasakul","year":"2018","journal-title":"Hematology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15006","article-title":"ISTH Guidelines for the Diagnosis of Thrombotic Thrombocytopenic Purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/35097008","article-title":"Mutations in a Member of the ADAMTS Gene Family Cause Thrombotic Thrombocytopenic Purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1765","article-title":"Specific Von Willebrand Factor\u2013Cleaving Protease in Thrombotic Microangiopathies: A Study of 111 Cases","volume":"98","author":"Veyradier","year":"2001","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13956","article-title":"Pathophysiology of Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome","volume":"16","author":"Kremer Hovinga","year":"2018","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1538-7836.2011.04341.x","article-title":"Natural History of Upshaw-Schulman Syndrome Based on ADAMTS13 Gene Analysis in Japan","volume":"9","author":"Fujimura","year":"2011","journal-title":"J Thromb Haemostasis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0232637","DOI":"10.1371\/journal.pone.0232637","article-title":"Upshaw-Schulman Syndrome-Associated ADAMTS13 Variants Possess Proteolytic Activity at the Surface of Endothelial Cells and in Simulated Circulation","volume":"15","author":"Letzer","year":"2020","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1813013","article-title":"Hereditary Thrombotic Thrombocytopenic Purpura","volume":"381","author":"Kremer Hovinga","year":"2019","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.216796","article-title":"The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: Key Findings at Enrollment Until 2017","volume":"104","author":"Van Dorland","year":"2019","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13107","article-title":"Pediatric Thrombotic Thrombocytopenic Purpura","volume":"101","author":"Joly","year":"2018","journal-title":"Eur J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30125-9","article-title":"Child-Onset and Adolescent-Onset Acquired Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency: A Cohort Study of the French National Registry for Thrombotic Microangiopathy","volume":"3","author":"Joly","year":"2016","journal-title":"Lancet Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02653.x","article-title":"The Utility of Patient Characteristics in Predicting Severe ADAMTS13 Deficiency and Response to Plasma Exchange","volume":"50","author":"Bentley","year":"2010","journal-title":"Transfusion"},{"key":"B13","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic Thrombocytopenic Purpura: Diagnostic Criteria, Clinical Features, and Long-Term Outcomes From 1995 Through 2015","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic Thrombocytopenic Purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2020.2020.0348","article-title":"Comparison of Clinical Scoring Systems in the Management of Patients With Microangiopathic Hemolytic Anemia and Thrombocytopenia","volume":"38","author":"Baysal","year":"2021","journal-title":"Turkish J Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and External Validation of the PLASMIC Score for Rapid Assessment of Adults With Thrombotic Microangiopathies: A Cohort Study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13882","article-title":"External Validation of the PLASMIC Score: A Clinical Prediction Tool for Thrombotic Thrombocytopenic Purpura Diagnosis and Treatment","volume":"16","author":"Li","year":"2018","journal-title":"J Thromb Haemost"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1616","article-title":"Nonneutralizing Igm and Igg Antibodies to Von Willebrand Factor\u2013Cleaving Protease (ADAMTS-13) in a Patient With Thrombotic Thrombocytopenic Purpura","volume":"102","author":"Scheiflinger","year":"2003","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4165","article-title":"Epitope Mapping of ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura","volume":"103","author":"Klaus","year":"2004","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05217.x","article-title":"Von Willebrand Factor Cleaving Protease (ADAMTS-13) and ADAMTS-13 Neutralizing Autoantibodies in 100 Patients With Thrombotic Thrombocytopenic Purpura","volume":"127","author":"Peyvandi","year":"2004","journal-title":"Br J Haematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-006064","article-title":"Prognostic Value of Anti-ADAMTS13 Antibody Features (Ig Isotype, Titer, and Inhibitory Effect) in a Cohort of 35 Adult French Patients Undergoing a First Episode of Thrombotic Microangiopathy With Undetectable ADAMTS13 Activity","volume":"109","author":"Ferrari","year":"2007","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13658","article-title":"Impact of Severe ADAMTS13 Deficiency on Clinical Presentation and Outcomes in Patients With Thrombotic Microangiopathies: The Experience of the Harvard TMA Research Collaborative","volume":"171","author":"Bendapudi","year":"2015","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in Acute Refractory and Relapsing Thrombotic Thrombocytopenic Purpura Following Rituximab is Associated With a Reduction in Igg Antibodies to ADAMTS-13","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1160\/TH06-06-0317","article-title":"The Efficacy of Rituximab in the Treatment of Inhibitor-Associated Hemostatic Disorders","volume":"96","author":"Franchini","year":"2006","journal-title":"Thromb Haemost"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1160\/TH06-09-0499","article-title":"Addition of Rituximab to Standard Therapy Improves Response Rate and Progression-Free Survival in Relapsed or Refractory Thrombotic Thrombocytopenic Purpura and Autoimmune Haemolytic Anaemia","volume":"97","author":"Von Auer","year":"2007","journal-title":"Thromb Haemostasis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13408","article-title":"A Phase-II Sequential Case-Series Study of All Patients Presenting to Four Plasma Exchange Centres With Presumed Relapsed\/Refractory Thrombotic Thrombocytopenic Purpura Treated With Rituximab","volume":"170","author":"Clark","year":"2015","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.629","article-title":"A Canadian Phase II Study Evaluating the Efficacy of Rituximab in the Management of Patients With Relapsed\/Refractory Thrombotic Thrombocytopenic Purpura","volume":"75","author":"Foley","year":"2009","journal-title":"Kidney Int"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15010","article-title":"ISTH Guidelines for Treatment of Thrombotic Thrombocytopenic Purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-420943","article-title":"Evaluation of Efficacy and Safety of the Anti-VWF Nanobody ALX-0681 in a Preclinical Baboon Model of Acquired Thrombotic Thrombocytopenic Purpura","volume":"120","author":"Callewaert","year":"2012","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15363","article-title":"Intracranial Hemorrhage in Immune Thrombotic Thrombocytopenic Purpura Treated With Caplacizumab","volume":"19","author":"Schofield","year":"2021","journal-title":"J Thromb Haemostasis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007599","article-title":"Real-World Experience With Caplacizumab in the Management of Acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009801","article-title":"Annual Incidence and Severity of Acute Episodes in Hereditary Thrombotic Thrombocytopenic Purpura","volume":"137","author":"Tarasco","year":"2021","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06264.x","article-title":"The Use of Intermediate Purity Factor VIII Concentrate BPL 8Y as Prophylaxis and Treatment in Congenital Thrombotic Thrombocytopenic Purpura","volume":"135","author":"Scully","year":"2006","journal-title":"Br J Haematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03809.x","article-title":"Successful Treatment of Congenital Thrombotic Thrombocytopenic Purpura Using the Intermediate Purity Factor VIII Concentrate BPL 8Y","volume":"119","author":"Lester","year":"2002","journal-title":"Br J Haematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23527","article-title":"ADAMTS13 Content in Plasma-Derived Factor VIII\/Von Willebrand Factor Concentrates","volume":"88","author":"Peyvandi","year":"2013","journal-title":"Am J Hematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: First-in-Human Pharmacokinetics and Safety in Congenital Thrombotic Thrombocytopenic Purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.836960\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T06:14:46Z","timestamp":1649657686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.836960\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2022.836960"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.836960","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"article-number":"836960"}}